Cramer pushes back on GE Vernova downgrade, says bonds matter most in shutdown

Despite government shutdown concerns, the S&P 500 was little changed as Treasury yields fell on a surprising 32,000 decline in September private sector jobs (ADP data), potentially delaying Friday's nonfarm report. Nike's strong earnings buoyed confidence, while GE Vernova dropped 2.5% post-RBC downgrade, though Jim Cramer remained bullish on its AI data center exposure. The pharma sector rallied broadly after Pfizer's White House deal on drug costs and US manufacturing, yet Bristol Myers Squibb was trimmed due to uncertainties surrounding its new schizophrenia treatment, Cobenfy.

Analysis

Market focus is narrowly centered on interest rate movements rather than the U.S. government shutdown, with the S&P 500 remaining stable. The key catalyst is a drop in Treasury yields following a surprising ADP report indicating a 32,000 decline in private sector jobs for September, suggesting a potential softening in the labor market. This economic signal is currently outweighing political risks, although the shutdown could delay the upcoming nonfarm jobs report. On a company-specific level, Nike's (NKE) strong earnings have bolstered investor confidence in its turnaround. In contrast, GE Vernova (GEV) declined roughly 2.5% after an RBC Capital downgrade to 'hold' on valuation concerns, a move contested by a bullish outlook on its long-term positioning to power AI data centers. Within the pharmaceutical sector, a positive regulatory signal from Pfizer's (PFE) deal with the White House has lifted peers like Eli Lilly (LLY), but company-specific risks persist, as demonstrated by the cautious trimming of Bristol Myers Squibb (BMY) positions ahead of performance updates for its new drug, Cobenfy.

Key Decisions for Investors

• Investors should prioritize monitoring key economic indicators, as market reactions suggest labor market data will be a primary driver of near-term volatility over the political noise of the government shutdown.
• For GE Vernova, one must weigh the near-term valuation concerns raised by RBC's downgrade against the long-term secular growth thesis tied to AI-driven energy demand.
• While the pharmaceutical sector is benefiting from a favorable regulatory development, the caution on Bristol Myers Squibb underscores the need to scrutinize individual drug pipelines and product launch performance, like that of Cobenfy, before increasing exposure.
• Nike's strong earnings provide a positive data point supporting its recovery narrative, making it a stock to consider for investors with a constructive view on consumer discretionary spending and brand strength.